BioNTech SE (BioNTech SE) Receivables Turnover : 0.10 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioNTech SE's Revenue for the three months ended in Mar. 2024 was $204 Mil. BioNTech SE's average Accounts Receivable for the three months ended in Mar. 2024 was $2,067 Mil. Hence, BioNTech SE's Receivables Turnover for the three months ended in Mar. 2024 was 0.10.

BioNTech SE Receivables Turnover Historical Data

The historical data trend for BioNTech SE's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Receivables Turnover Chart

BioNTech SE Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

6.94

5.47

3.02

1.70

0.84

BioNTech SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															0.19	0.04	0.38	0.72	0.10

Competitive Comparison of BioNTech SE's Receivables Turnover

For the Biotechnology subindustry, BioNTech SE's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNTech SE's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioNTech SE's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where BioNTech SE's Receivables Turnover falls into.

BioNTech SE Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

BioNTech SE's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	4164.667	/ (	(7569.492	+	2350.818)	/	2 )
=	4164.667	/	4960.155
=	0.84

BioNTech SE's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	203.913	/ (	(2350.818	+	1782.391)	/	2 )
=	203.913	/	2066.6045
=	0.10

BioNTech SE (NAS:BNTX) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

BioNTech SE Receivables Turnover Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria

Address

An der Goldgrube 12, Mainz, RP, DEU, D-55131

Website

https://www.biontech.de

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.